منابع مشابه
COX-2 in cardiovascular disease.
Prostanoids are a large family of lipid mediators derived from the arachidonic acid metabolites of the cyclooxygenase (COX) enzymes. Therapeutically, COX is the target of the nonsteroid antiinflammatory drugs (NSAIDs), a chemically diverse group that includes ibuprofen, naproxen, and diclofenac, among dozens of others. Inhibition of prostanoid production by traditional NSAIDs accounts for all t...
متن کاملThe cardiovascular pharmacology of COX-2 inhibition.
Selective inhibitors of cyclooxygenase (COX)-2, the coxibs, were developed to inhibit inflammatory prostaglandins derived from COX-2, while sparing gastroprotective prostaglandins primarily formed by COX-1. However, COX-2-derived prostaglandins mediate not only pain and inflammation but also affect vascular function, the regulation of hemostasis/ thrombosis, and blood pressure control. All coxi...
متن کاملCox-2 Inhibitors and Cardiovascular Risks
The controversy over the cardiovascular risks of cox-2 inhibitors stems from 2 main trials: VIGOR and CLASS. These two trials were designed to assess the gastrointestinal safety of rofecoxib (Vioxx) and celecoxib (Celebrex), respectively. From these trials, it was observed that the cox-2 inhibitors had a higher number of cardiovascular events than the NSAIDS that they were paired against. For e...
متن کاملCox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors
Selective cyclooxygenase-2 (COX-2) inhibitors were developed to reduce the gastrointestinal toxicity of conventional nonsteroidal anti-inflammatory agents. However, COX-2 inhibitors decrease prostacyclin production and may disrupt the normal homeostatic balance, leading to a prothrombotic state and offsetting the potential gastrointestinal benefits. Available clinical data and basic biological ...
متن کاملCell Therapy in Cardiovascular Disease
Recently, cell therapy has sparked a revolution in ischemic heart disease that will in the future help clinicians to cure patients. Earlier investigations in animal models and clinical trials have suggested that positive paracrine effects such as neoangiogenesis and anti-apoptotic can improve myocardial function. In this regard the Royan cell therapy center designed a few trials in collaborat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arteriosclerosis, Thrombosis, and Vascular Biology
سال: 2006
ISSN: 1079-5642,1524-4636
DOI: 10.1161/01.atv.0000219672.68024.bc